PolymarketKapalıKullanılabilirliği kontrol etKYC yokDoğrulanmış sonuçlanma verisiİyi kalibreBu piyasa sonuçlandı: No
Sonuçlandı: 11 Haz 2026 09:52
Sağlayıcı tarafından doğrulanmış sonuç
CoinRithm bu piyasa için kazanan ve sonuçlanma zamanı konusunda sağlayıcı destekli kanıta sahip.
Kazanan Sonuç
No
7 gün kala
—
24 saat kala
8%
SürprizOlasılık Zaman Çizelgesi
Yes0%
No100%
HayırKazandı
EvetKaybetti
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
Will GiveWell fund Intermittent preventive treatment in infants (IPTi) for malaria by 1st January 2027?
Manifold Markets[ACX 2026] Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?
Manifold MarketsDid COVID-19 come from a laboratory?
Manifold MarketsAnthropic lab leak by which date?
PolymarketWill the FDA approve retatrutide?
KalshiWill GiveWell fund probiotic supplementation for preterm newborns by 1st January 2027?
Manifold MarketsKurallar
As of market creation, the FDA's expected decision date for the specified application is June 10, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Camurus's Oclaiz as a treatment for patients with acromegaly by June 24, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs